Published in Cancer Cell on July 01, 2003
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer (2007) 3.28
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.20
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival. Genes Dev (2005) 2.37
Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol (2007) 2.07
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A (2005) 2.07
Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol (2006) 1.89
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.70
A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev (2006) 1.70
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A (2006) 1.67
Regulation of cartilage-specific gene expression in human chondrocytes by SirT1 and nicotinamide phosphoribosyltransferase. J Biol Chem (2008) 1.66
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol (2008) 1.59
Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein. Mol Cell Biol (2005) 1.52
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res (2009) 1.38
Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother (2007) 1.38
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood (2008) 1.34
Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin Epigenetics (2011) 1.31
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res (2011) 1.30
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs (2010) 1.27
Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol Cell Biol (2004) 1.26
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther (2008) 1.26
Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res (2010) 1.22
Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer (2006) 1.18
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol (2006) 1.13
Histone deacetylase inhibitors through click chemistry. J Med Chem (2008) 1.10
Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol (2013) 1.09
Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer (2008) 1.09
Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites. J Exp Med (2009) 1.08
Current therapy of myelodysplastic syndromes. Blood Rev (2013) 1.07
Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med (2008) 1.06
HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm (2009) 1.06
CREB-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor trichostatin A. Neoplasia (2007) 1.05
Genomic targets, and histone acetylation and gene expression profiling of neural HDAC inhibition. Nucleic Acids Res (2013) 1.05
Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs (2010) 1.05
Chromatin-modifying enzymes as therapeutic targets--Part 1. Expert Opin Ther Targets (2008) 1.04
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol (2007) 1.04
Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol (2011) 1.03
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol (2011) 1.02
Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol (2010) 1.02
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals (Basel) (2010) 1.02
Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol Cancer (2010) 1.01
The APC/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis. Front Oncol (2012) 1.01
Epigenetics: an emerging player in gastric cancer. World J Gastroenterol (2014) 1.01
Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle (2006) 1.01
Chemopreventive agent 3,3'-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res (2010) 1.00
Novel therapeutic agents for cutaneous T-Cell lymphoma. J Hematol Oncol (2012) 0.98
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood (2015) 0.98
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica (2010) 0.98
Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Mol Carcinog (2013) 0.97
On the function of the internal cavity of histone deacetylase protein 8: R37 is a crucial residue for catalysis. Bioorg Med Chem Lett (2011) 0.97
3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prev Res (Phila) (2009) 0.95
Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. Br J Cancer (2010) 0.94
Epigenetics: new questions on the response to hypoxia. Int J Mol Sci (2011) 0.93
Diverse roles of C-terminal Hsp70-interacting protein (CHIP) in tumorigenesis. J Cancer Res Clin Oncol (2013) 0.91
A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. Invest New Drugs (2011) 0.89
Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin (Shanghai) (2015) 0.88
Inhibition and mechanism of HDAC8 revisited. J Am Chem Soc (2014) 0.88
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer (2011) 0.87
Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog. Genes Cancer (2015) 0.86
The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. Nucl Med Biol (2011) 0.86
Molecular targets for tumor radiosensitization. Chem Rev (2009) 0.86
Trichostatin A targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cells. PLoS One (2014) 0.86
ATM modulates transcription in response to histone deacetylase inhibition as part of its DNA damage response. Exp Mol Med (2010) 0.85
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol (2012) 0.85
Effects of SAHA on proliferation and apoptosis of hepatocellular carcinoma cells and hepatitis B virus replication. World J Gastroenterol (2013) 0.85
Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer. Front Oncol (2013) 0.84
Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? J Biomed Biotechnol (2011) 0.83
Design and synthesis of novel hybrid benzamide-peptide histone deacetylase inhibitors. Bioorg Med Chem Lett (2009) 0.83
Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS One (2011) 0.83
Ferritin H induction by histone deacetylase inhibitors. Biochem Pharmacol (2010) 0.82
Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy. Antioxid Redox Signal (2014) 0.82
Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation. Anal Chem (2008) 0.82
Manipulating the epigenome for the treatment of urological malignancies. Pharmacol Ther (2013) 0.81
Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol (2011) 0.81
Epigenetics and Cellular Metabolism. Genet Epigenet (2016) 0.80
Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells. Antioxid Redox Signal (2014) 0.80
SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Cancer Biol Ther (2014) 0.79
Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide. Bioorg Med Chem Lett (2009) 0.79
Is glioblastoma an epigenetic malignancy? Cancers (Basel) (2013) 0.79
Genome-wide association study identifies possible genetic risk factors for colorectal adenomas. Cancer Epidemiol Biomarkers Prev (2013) 0.78
Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model. Strahlenther Onkol (2013) 0.78
The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer. Oncotarget (2016) 0.78
Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells. J Cell Biochem (2016) 0.78
Radiosensitization of yeast cells by inhibition of histone h4 acetylation. Radiat Res (2008) 0.77
The DAC system and associations with acute leukemias and myelodysplastic syndromes. Invest New Drugs (2010) 0.77
Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer Discov (2016) 0.77
Anti-Cancer Effect of IN-2001 in T47D Human Breast Cancer. Biomol Ther (Seoul) (2012) 0.77
Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer. Biomol Ther (Seoul) (2012) 0.77
Vorinostat-An Overview. Indian J Dermatol (2015) 0.77
Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy. Radiat Oncol (2015) 0.76
DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics. Scientifica (Cairo) (2016) 0.76
Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors. Onco Targets Ther (2013) 0.76
Update on occult hepatitis B virus infection. World J Gastroenterol (2016) 0.75
Effects of Histone Deacetylase Inhibitor (Valproic Acid) on the Expression of Hypoxia-inducible Factor-1 Alpha in Human Retinal Müller Cells. Korean J Ophthalmol (2017) 0.75
Epigenetics in cancer stem cells. Mol Cancer (2017) 0.75
PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer. Oncotarget (2017) 0.75
Technical advances in trigger-induced RNA interference gene silencing in the parasite Entamoeba histolytica. Int J Parasitol (2015) 0.75
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet (2003) 5.16
Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity (2013) 4.08
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol (2005) 3.14
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med (2004) 3.10
Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Dev Cell (2005) 2.95
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell (2003) 2.20
Sprouty1 regulates reversible quiescence of a self-renewing adult muscle stem cell pool during regeneration. Cell Stem Cell (2010) 2.03
HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest (2010) 2.00
Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol (2003) 2.00
Ret-dependent cell rearrangements in the Wolffian duct epithelium initiate ureteric bud morphogenesis. Dev Cell (2009) 1.81
miR-27b controls venous specification and tip cell fate. Blood (2011) 1.79
CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol (2004) 1.72
Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol Cell Biol (2002) 1.70
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med (2012) 1.69
Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1. Dev Biol (2006) 1.61
Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol (2003) 1.61
Survivin is not required for the endomitotic cell cycle of megakaryocytes. Blood (2009) 1.57
The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol Cell (2013) 1.54
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res (2004) 1.51
Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov (2012) 1.43
Kidney development in the absence of Gdnf and Spry1 requires Fgf10. PLoS Genet (2010) 1.40
PLZF is a regulator of homeostatic and cytokine-induced myeloid development. Genes Dev (2009) 1.35
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1. Proc Natl Acad Sci U S A (2009) 1.26
Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol (2002) 1.26
Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor signaling: a dual feedback loop. Mol Biol Cell (2004) 1.24
Deregulation of H3K27 methylation in cancer. Nat Genet (2010) 1.23
Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity (2009) 1.22
HOX deregulation in acute myeloid leukemia. J Clin Invest (2007) 1.20
ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood (2003) 1.19
WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak. Cancer Res (2005) 1.18
WT1 activates a glomerular-specific enhancer identified from the human nephrin gene. J Am Soc Nephrol (2004) 1.17
Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. J Virol (2007) 1.14
The receptor tyrosine kinase regulator Sprouty1 is a target of the tumor suppressor WT1 and important for kidney development. J Biol Chem (2003) 1.12
Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3. Proc Natl Acad Sci U S A (2012) 1.12
The LIM-only protein DRAL/FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger protein. J Biol Chem (2002) 1.11
DNMT3A mutations in acute myeloid leukemia. Nat Genet (2011) 1.11
Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood (2009) 1.06
Sprouty proteins inhibit receptor-mediated activation of phosphatidylinositol-specific phospholipase C. Mol Biol Cell (2010) 1.06
Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood (2008) 1.04
BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. J Biol Chem (2003) 1.00
PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein. Oncogene (2002) 0.98
Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin Cancer Res (2010) 0.95
New molecular concepts and targets in acute myeloid leukemia. Curr Opin Hematol (2008) 0.95
Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6. Leuk Res (2005) 0.93
The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood (2004) 0.91
The theoretical basis of transcriptional therapy of cancer: can it be put into practice? J Clin Oncol (2005) 0.90
Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. J Biol Chem (2012) 0.90
Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia. Clin Cancer Res (2013) 0.89
Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. Curr Opin Hematol (2005) 0.89
Spry1 and Spry2 are necessary for lens vesicle separation and corneal differentiation. Invest Ophthalmol Vis Sci (2011) 0.88
Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5. Biochem Biophys Res Commun (2004) 0.87
A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16. Neoplasia (2008) 0.87
The effects of the Fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis, and proliferation are differentiation stage-specific. J Biol Chem (2002) 0.86
Chromatin modulation by oncogenic transcription factors: new complexity, new therapeutic targets. Cancer Cell (2007) 0.86
WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression. Mol Cancer Res (2008) 0.85
Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitor-induced DNA damage and apoptosis. Mol Cancer Ther (2013) 0.85
Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors. J Biol Chem (2013) 0.84
Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2. Blood (2012) 0.83
Computational identification of Ftz/Ftz-F1 downstream target genes. Dev Biol (2006) 0.83
Molecular characterization of acute myeloid leukemia and its impact on treatment. Curr Opin Oncol (2007) 0.83
Spry1 and Spry2 are necessary for eyelid closure. Dev Biol (2013) 0.81
Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Pract Res Clin Haematol (2003) 0.81
G Protein-regulated inducer of neurite outgrowth (GRIN) modulates Sprouty protein repression of mitogen-activated protein kinase (MAPK) activation by growth factor stimulation. J Biol Chem (2012) 0.80
Regulation of CD4⁺ and CD8⁺ effector responses by Sprouty-1. PLoS One (2012) 0.78
New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapy. Clin Cancer Res (2012) 0.77
MEK and MAF in myeloma therapy. Blood (2011) 0.77
Epigenetic therapy of hematological malignancies: where are we now? Ther Adv Hematol (2013) 0.77
Partners in crime: Genes within an amplicon collude to globally deregulate chromatin in lymphoma. Cancer Cell (2010) 0.75
Despite WT1 binding sites in the promoter region of human and mouse nucleoporin glycoprotein 210, WT1 does not influence expression of GP210. J Negat Results Biomed (2004) 0.75
Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma. Curr Opin Hematol (2017) 0.75